Facebook
Facebook
This 2009 NCDEU Poster Session was published in September 2009 and is eligible for AMA PRA Category 1 Credit through March 31, 2010. The latest review of this material was September 2009.
To obtain credit for this activity, study the material and complete the CME Posttest and Evaluation.
After completing this educational activity, you should be able to:
This special 2009 NCDEU Annual Meeting Poster Session was developed for CME credit designation on the basis of our assessment of the needs of Web site visitors, with the purpose of providing visitors with a curriculum of posters on a variety of topics.
The CME Institute of Physicians Postgraduate Press, Inc., is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The CME Institute of Physicians Postgraduate Press, Inc., designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The presenters for this CME activity and the CME Institute staff were asked to complete a statement regarding all relevant personal financial relationships between themselves and their spouse/partner and any commercial interest. The CME Institute has resolved any conflicts of interest that were identified. No member of the CME Institute staff reported any relevant personal financial relationships. Financial disclosures from the presenters are as follows:
Ms DeVeaugh-Geiss has received grant/research support from NIMH and M-3 Information, and is a stock shareholder of GlaxoSmithKline and Pozen. Her spouse is a consultant for Schwarz Biosciences, Cenerex, Neuropharm, and Brain Cells, and is a stock shareholder of GlaxoSmithKline and Pozen.
Dr Gaynes is a consultant for Bristol-Myers Squibb and has received grant/research support from NIMH, AHCRQ, Bristol-Myers Squibb, Novartis, and M-3 Information.
Dr Gu is a consultant for Pfizer and has received grant/research support from NIH and M-3 Information.
Dr Kafantaris has received grant/research support from AstraZeneca, Eli Lilly, Pfizer, Janssen, and GlaxoSmithKline.
Dr Kane is a consultant for AstraZeneca, Bristol-Myers Squibb, Otsuka, Johnson & Johnson, Janssen, Cephalon, Eli Lilly, Wyeth, Proteus, and Lundbeck and has received honoraria from Janssen, Eli Lilly, Otsuka, and Bristol-Myers Squibb.
Dr Kumra is a consultant for AstraZeneca and Schering Plough.
Dr Malone has received grant/research support from Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, and the NIMH.
Dr Rubinow is a member of the editorial board for Dialogues in Clinical Neuroscience; has received grant/research support from NIH, NIMH, and the Foundation of Hope; is a member of the advisory board for Depression and Bipolar Support; and is a stock shareholder of Amgen and Vanguard Special Mental Health Fund.
Dr D. Sheehan is a consultant for Abbott, Treatment Drug and Assessment Research Review, Alexa, Alza, American Psychiatric Association Task Force on Benzodiazepine Dependency, American Psychiatric Association Task Force on Treatments of Psychiatric Disorders, American Psychiatric Association Working Group to revise DSM-III Anxiety Disorders Section, Anxiety Disorders Resource Center, Anxiety Drug Efficacy Case for the US FDA, Applied Health Outcomes/XCENDA, AstraZeneca, Avera, Bristol-Myers Squibb, Cephalon, Committee (RRC) of NIMH on Anxiety and Phobic Disorder Projects, Connecticut and Ohio Academies of Family Physicians, Cortex, Council on Anxiety Disorders, CPC Coliseum Medical Center, Cypress Bioscience, Division of Drugs and Technology for the American Medical Association, EISAI, Faxmed, Forest, GlaxoSmithKline, INC Research, International Society for CNS Drug Development (ISCDD), Janssen, Jazz, Labopharm, Layton Bioscience, Eli Lilly Research Laboratories, Lundbeck, MediciNova, National Anxiety Awareness Program, National Anxiety Foundation, National Depressive and Manic Depressive Association, Organon, Orion, Parexel International, Pfizer, Pharmacia, Philadelphia College of Pharmacy and Science, Pierre Fabre, Roche, Sanofi-Aventis, Sanofi-Synthelabo Recherche, Sepracor, Shire, SmithKlineBeecham, Solvay, Takeda, Tampa General Hospital, Targacept, Tikvah Therapeutics, Titan, Upjohn Company, US Congress House of Representatives Committee, Board of Trustees for USF Friends of Research in Psychiatry, World Health Organization, Wyeth-Ayerst, ZARS, and Neuronetics; has received grant/research support from Abbott, American Medical Association, Anclote Foundation, AstraZeneca, Avera, Bristol-Myers Squibb, Burroughs Wellcome, EISAI, Eli Lilly, Forest, GlaxoSmithKline, Glaxo-Wellcome, International Clinical Research (ICR), Janssen, Jazz, Kali-Duphar, Mead Johnson, MediciNova, Merck Sharpe and Dohme, NIDA, NIH, Novartis, Parke-Davis, Pfizer, Quintiles, Sandoz, Sanofi-Aventis, Sanofi-Synthelabo Recherche, SmithKlineBeecham, Psychiatry Center at the University of South Florida College of Medicine, TAP, United Bioscience, Upjohn Company, Warner Chilcott, Worldwide Clinical Trials, Wyeth-Ayerst, and Zeneca; has given lectures/presentations for Abbott, AstraZeneca, Boehringer Ingelheim, Boots, Bristol-Myers Squibb, Burroughs Wellcome, Charter Hospitals, Ciba Geigy, Dista Products, Eli Lilly, Excerpta Medica Asia, Glaxo Pharmaceuticals, GlaxoSmithKline, Hospital Corporation of America, Humana, ICI, Janssen, Kali-Duphar, Marion Merrill Dow, McNeil, Mead Johnson, Merck Sharpe and Dohme, Novo Nordisk, Organon, Parke-Davis, Pfizer, Pharmacia and Upjohn, Rhone Laboratories, Rhone-Poulenc Rorer Pharmaceuticals, Roerig, Sandoz, Sanofi-Aventis, Schering, SmithKlineBeecham, Solvay, TAP, TGH University Psychiatry Center, Upjohn Company, and Warner Chilcott; and is a stock holder of Medical Outcome Systems.
Dr K. Sheehan has received grant/research support from GlaxoSmithKline.
Dr Stock has received grant/research support from GlaxoSmithKline and Bristol-Myers Squibb, and has received honoraria from and is a member of the speakers/advisory boards for Janssen, Ortho-McNeil, and Bristol-Myers Squibb.
Dr Wixsom is a member of the speakers bureau for Janssen.
Drs Delaney, Gallelli, Ghaffari, Hardison, Hirsch, Janavs, Khan, Lawrence, Leigh, Newschaffer, Rogers, Saito, Shytle, Weir, West, and Wilkinson and Ms Bannon, Berest, Dombrowski, and Katsiotas have no personal financial relationships to disclose relative to this presentation.
In this 2009 NCDEU Poster Session, participants may be presenting investigational information about pharmaceutical agents that is outside US Food and Administration–labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
This 2009 NCDEU Poster Session has been reviewed for accuracy and fair balance by a selection committee of the American Society of Clinical Psychopharmacology (ASCP), and a member of the External CME Advisory Board has reviewed this poster session to determine whether the material is evidence-based and objective.
This 2009 NCDEU Poster Session is derived from the 49th Annual NCDEU Meeting, which was held June 29–July 2, 2009, in Hollywood, Florida, and was independently developed by the CME Institute of Physicians Postgraduate Press, Inc., the National Institute of Mental Health (NIMH), and the ASCP. The opinions expressed herein are those of the presenters and do not necessarily reflect the opinions of the CME provider and publisher, the NIMH, or the ASCP.
Psychiatrist.com Home
Keyword Search